Search

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

Jun 14 2013

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

EHA Kick-off Grant review and selection process

1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Jun 12 2015 Posted in Press releases

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.

EHA Innovation Grant

The call for applications is closed. The EHA Innovation Grant is intended to encourage and support the creation of consortia and the generation of preliminary data to facilitate applying for larger funding opportunities.

EHA Congratulates EHA Kick-Off Grant 2021 Winners

Jan 04 2022 Posted in Press releases

The Hague, January 3, 2022 –EHA Congratulates seven talented researchers in Hematology on their receipt of an EHA Kick-Off Grant 2021 after a rigorous selection process.

Compliance and reports

EHA is a non-governmental and not-for-profit membership organization that is guided by its mission to promote excellence in patient care, research, and education in hematology.